Back

Which patients will benefit most from FXI inhibition?

29 August 2022 (15:50 - 16:05)
Organised by:
Congress Presentation Part of: How could factor eleven (FXI) inhibitors help your patients? New frontiers in thrombosis prevention Atrial Fibrillation (AF) Open Access ESC Congress 2022

About the speaker

Photo
Professor Vijay Kunadian

Newcastle University, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Welcome and introduction.
Doctor M. Patel (Durham, US)
Presentation thumbnail
What makes FXI inhibition different from current approaches to thrombosis prevention?
Professor V. Caso (Perugia, IT)
Presentation thumbnail
Live Q&A.

Access the full session

Session thumbnail
How could factor eleven (FXI) inhibitors help your patients? New frontiers in thrombosis prevention

The Event

Event poster

ESC Congress 2022

29 August 2022 15:50 CET
You may be interested in
thumbnail
Congress Presentation
Factor XI inhibitors or direct oral anticoagulants in atrial fibrillation: an updated meta-analysis
1 September 2025
thumbnail
Congress Session
Cardiology Toolbox: managing heparin-induced thrombocytopaenia (HIT), factor V Leiden, and antiphospholipid syndromes in cardiovascular medicine
2 September 2024
thumbnail
Congress Presentation
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
1 September 2025
thumbnail
Congress Session
Will we see a new paradigm for stroke prevention in atrial fibrillation? Which patients are more likely to benefit from FXIa inhibition vs DOACs?
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources